Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Opposing Roles of apolipoprotein E in aging and neurodegeneration.

Hudry E, Klickstein J, Cannavo C, Jackson R, Muzikansky A, Gandhi S, Urick D, Sargent T, Wrobleski L, Roe AD, Hou SS, Kuchibhotla KV, Betensky RA, Spires-Jones T, Hyman BT.

Life Sci Alliance. 2019 Feb 13;2(1). pii: e201900325. doi: 10.26508/lsa.201900325. Print 2019 Feb.

2.

Fluorescence Polarization of Methylene Blue as a Quantitative Marker of Breast Cancer at the Cellular Level.

Yaroslavsky AN, Feng X, Muzikansky A, Hamblin MR.

Sci Rep. 2019 Jan 30;9(1):940. doi: 10.1038/s41598-018-38265-0.

3.

Randomized Trial of a Tailored Cognitive-Behavioral Therapy Mobile Application for Anxiety in Patients with Incurable Cancer.

Greer JA, Jacobs J, Pensak N, MacDonald JJ, Fuh CX, Perez GK, Ward A, Tallen C, Muzikansky A, Traeger L, Penedo FJ, El-Jawahri A, Safren SA, Pirl WF, Temel JS.

Oncologist. 2019 Jan 25. pii: theoncologist.2018-0536. doi: 10.1634/theoncologist.2018-0536. [Epub ahead of print]

PMID:
30683710
4.

Performance of a Hospital Pathway for Patients With a New Single Brain Mass.

Arrillaga-Romany I, Curry WT Jr, Jordan JT, Cahill DP, Nahed BV, Martuza RL, Loeffler JS, Järhult SJ, Muzikansky A, Cohen AB, Singhal AB, Goldstein JN, Batchelor TT.

J Oncol Pract. 2019 Mar;15(3):e211-e218. doi: 10.1200/JOP.17.00098. Epub 2019 Jan 25.

PMID:
30681891
5.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV.

J Clin Oncol. 2019 Feb 1;37(4):278-285. doi: 10.1200/JCO.18.01585. Epub 2018 Dec 14.

PMID:
30550363
6.

Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer.

Lichtenstein MRL, Nipp RD, Muzikansky A, Goodwin K, Anderson D, Newcomb RA, Gainor JF.

J Thorac Oncol. 2019 Mar;14(3):547-552. doi: 10.1016/j.jtho.2018.11.011. Epub 2018 Nov 23.

PMID:
30476576
7.

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, Shapiro MA, Muzikansky A, Murthy S, Lanuti M, Rusch VW, Kris MG, Sequist LV.

J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16. Erratum in: J Clin Oncol. 2019 Mar 1;37(7):612.

PMID:
30444685
8.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.

Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV.

Ann Oncol. 2018 Oct 1;29(10):2092-2097. doi: 10.1093/annonc/mdy336.

PMID:
30351341
9.

Physical symptoms in long-term survivors of rare cancer.

Horick NK, Muzikansky A, Gutierrez HL, Boyd KL, Finkelstein DM.

J Cancer Surviv. 2018 Dec;12(6):835-842. doi: 10.1007/s11764-018-0721-9. Epub 2018 Oct 12.

PMID:
30315392
10.

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.

Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX.

Clin Cancer Res. 2019 Jan 1;25(1):80-89. doi: 10.1158/1078-0432.CCR-18-0847. Epub 2018 Sep 6.

PMID:
30190369
11.

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma.

Lee EQ, Duda DG, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey S, Batchelor TT, Jain RK, Wen PY.

Clin Cancer Res. 2018 Oct 1;24(19):4643-4649. doi: 10.1158/1078-0432.CCR-18-1025. Epub 2018 Jun 25.

PMID:
29941486
12.

Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results.

Schwamm LH, Wu O, Song SS, Latour LL, Ford AL, Hsia AW, Muzikansky A, Betensky RA, Yoo AJ, Lev MH, Boulouis G, Lauer A, Cougo P, Copen WA, Harris GJ, Warach S; MR WITNESS Investigators.

Ann Neurol. 2018 May;83(5):980-993. doi: 10.1002/ana.25235. Epub 2018 Apr 27.

PMID:
29689135
13.

Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.

Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Wu L, Zhao F, Zhao Y, Zhang Y, Zhang J, Fujita T, Stemmer-Rachamimov A, Ferraro GB, Liu H, Muzikansky A, Plotkin SR, Stankovic KM, Jain RK, Xu L.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2077-E2084. doi: 10.1073/pnas.1719966115. Epub 2018 Feb 9.

14.

Impaired memory is more closely associated with brain beta-amyloid than leukoaraiosis in hypertensive patients with cognitive symptoms.

Smith EE, Muzikansky A, McCreary CR, Batool S, Viswanathan A, Dickerson BC, Johnson K, Greenberg SM, Blacker D.

PLoS One. 2018 Jan 30;13(1):e0191345. doi: 10.1371/journal.pone.0191345. eCollection 2018.

15.

Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.

Reardon DA, Lassman AB, Schiff D, Yunus SA, Gerstner ER, Cloughesy TF, Lee EQ, Gaffey SC, Barrs J, Bruno J, Muzikansky A, Duda DG, Jain RK, Wen PY.

Cancer. 2018 Apr 1;124(7):1438-1448. doi: 10.1002/cncr.31172. Epub 2017 Dec 19.

PMID:
29266174
16.

Role of Patient Coping Strategies in Understanding the Effects of Early Palliative Care on Quality of Life and Mood.

Greer JA, Jacobs JM, El-Jawahri A, Nipp RD, Gallagher ER, Pirl WF, Park ER, Muzikansky A, Jacobsen JC, Jackson VA, Temel JS.

J Clin Oncol. 2018 Jan 1;36(1):53-60. doi: 10.1200/JCO.2017.73.7221. Epub 2017 Nov 15.

17.

Effects of Early Integrated Palliative Care on Caregivers of Patients with Lung and Gastrointestinal Cancer: A Randomized Clinical Trial.

El-Jawahri A, Greer JA, Pirl WF, Park ER, Jackson VA, Back AL, Kamdar M, Jacobsen J, Chittenden EH, Rinaldi SP, Gallagher ER, Eusebio JR, Fishman S, VanDusen H, Li Z, Muzikansky A, Temel JS.

Oncologist. 2017 Dec;22(12):1528-1534. doi: 10.1634/theoncologist.2017-0227. Epub 2017 Sep 11.

18.

Differential UBE2C and HOXA1 expression in melanocytic nevi and melanoma.

Kraft S, Moore JB, Muzikansky A, Scott KL, Duncan LM.

J Cutan Pathol. 2017 Oct;44(10):843-850. doi: 10.1111/cup.12997. Epub 2017 Jul 21.

PMID:
28657121
19.

Lymphatic invasion predicts sentinel lymph node metastasis and adverse outcome in primary cutaneous melanoma.

Moy AP, Mochel MC, Muzikansky A, Duncan LM, Kraft S.

J Cutan Pathol. 2017 Sep;44(9):734-739. doi: 10.1111/cup.12969. Epub 2017 Jun 19.

PMID:
28555886
20.

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA.

Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Review.

21.

Soluble oligomeric amyloid-β induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain.

Arbel-Ornath M, Hudry E, Boivin JR, Hashimoto T, Takeda S, Kuchibhotla KV, Hou S, Lattarulo CR, Belcher AM, Shakerdge N, Trujillo PB, Muzikansky A, Betensky RA, Hyman BT, Bacskai BJ.

Mol Neurodegener. 2017 Mar 21;12(1):27. doi: 10.1186/s13024-017-0169-9.

22.

An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma.

Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, Milner JD, Hong X, Goyal L, Sil S, Choz M, Ho U, Kapur R, Muzikansky A, Zhang H, Weitz DA, Sequist LV, Ryan DP, Chung RT, Zhu AX, Isselbacher KJ, Ting DT, Toner M, Maheswaran S, Haber DA.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1123-1128. doi: 10.1073/pnas.1617032114. Epub 2017 Jan 17.

23.

Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial.

Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, Back AL, Kamdar M, Jacobsen J, Chittenden EH, Rinaldi SP, Gallagher ER, Eusebio JR, Li Z, Muzikansky A, Ryan DP.

J Clin Oncol. 2017 Mar 10;35(8):834-841. doi: 10.1200/JCO.2016.70.5046. Epub 2016 Dec 28.

24.

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.

Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER.

J Neurooncol. 2017 Feb;131(3):603-610. doi: 10.1007/s11060-016-2332-5. Epub 2016 Nov 16.

PMID:
27853960
25.

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.

Uruga H, Bozkurtlar E, Huynh TG, Muzikansky A, Goto Y, Gomez-Caraballo M, Hata AN, Gainor JF, Mark EJ, Engelman JA, Lanuti MD, Mino-Kenudson M.

J Thorac Oncol. 2017 Mar;12(3):458-466. doi: 10.1016/j.jtho.2016.10.015. Epub 2016 Nov 2.

26.

Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.

Campo M, Gerber D, Gainor JF, Heist RS, Temel JS, Shaw AT, Fidias P, Muzikansky A, Engelman JA, Sequist LV.

J Thorac Oncol. 2016 Nov;11(11):2022-2026. doi: 10.1016/j.jtho.2016.06.032. Epub 2016 Aug 20.

27.

Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.

Vaios EJ, Nahed BV, Muzikansky A, Fathi AT, Dietrich J.

J Neurosurg. 2017 Jul;127(1):132-138. doi: 10.3171/2016.7.JNS16609. Epub 2016 Oct 14.

PMID:
27739940
28.

End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.

Bauman JR, Piotrowska Z, Muzikansky A, Gallagher E, Scribner E, Temel B, Sequist LV, Heist RS, Temel JS.

J Palliat Med. 2016 Dec;19(12):1316-1319. Epub 2016 Sep 14.

PMID:
27626514
29.

Integrating tobacco treatment into cancer care: Study protocol for a randomized controlled comparative effectiveness trial.

Park ER, Ostroff JS, Perez GK, Hyland KA, Rigotti NA, Borderud S, Regan S, Muzikansky A, Friedman ER, Levy DE, Holland S, Eusebio J, Peterson L, Rabin J, Miller-Sobel J, Gonzalez I, Malloy L, O'Brien M, de León-Sanchez S, Whitlock CW.

Contemp Clin Trials. 2016 Sep;50:54-65. doi: 10.1016/j.cct.2016.07.016. Epub 2016 Jul 19.

30.

Cost Analysis of a Randomized Trial of Early Palliative Care in Patients with Metastatic Nonsmall-Cell Lung Cancer.

Greer JA, Tramontano AC, McMahon PM, Pirl WF, Jackson VA, El-Jawahri A, Parikh RB, Muzikansky A, Gallagher ER, Temel JS.

J Palliat Med. 2016 Aug;19(8):842-8. doi: 10.1089/jpm.2015.0476. Epub 2016 May 11.

PMID:
27167637
31.

Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum.

Serrano-Pozo A, Qian J, Muzikansky A, Monsell SE, Montine TJ, Frosch MP, Betensky RA, Hyman BT.

J Neuropathol Exp Neurol. 2016 Jun;75(6):516-26. doi: 10.1093/jnen/nlw026. Epub 2016 Apr 22.

32.

Health-related Quality of Life of Individuals With Neurofibromatosis Type 2: Results From the NF2 Natural History Study.

Merker VL, Bergner AL, Vranceanu AM, Muzikansky A, Slattery W 3rd, Plotkin SR.

Otol Neurotol. 2016 Jun;37(5):574-9. doi: 10.1097/MAO.0000000000001019.

PMID:
27050651
33.

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.

Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, Duda DG, Fukumura D, Batchelor TT, Jain RK.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4476-81. doi: 10.1073/pnas.1525360113. Epub 2016 Apr 4.

34.

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.

Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D, Jain RK.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4470-5. doi: 10.1073/pnas.1525349113. Epub 2016 Apr 4.

35.

Identification of the novel activity-driven interaction between synaptotagmin 1 and presenilin 1 links calcium, synapse, and amyloid beta.

Kuzuya A, Zoltowska KM, Post KL, Arimon M, Li X, Svirsky S, Maesako M, Muzikansky A, Gautam V, Kovacs D, Hyman BT, Berezovska O.

BMC Biol. 2016 Mar 31;14:25. doi: 10.1186/s12915-016-0248-3.

36.

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR.

J Clin Oncol. 2016 May 10;34(14):1669-75. doi: 10.1200/JCO.2015.64.3817. Epub 2016 Mar 14.

37.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.

Lee EQ, Muzikansky A, Drappatz J, Kesari S, Wong ET, Fadul CE, Reardon DA, Norden AD, Nayak L, Rinne ML, Alexander BM, Arvold ND, Doherty L, Stefanik J, LaFrankie D, Ruland SF, Pulverenti J, Smith KH, Gaffey SC, Hammond S, Wen PY.

Neuro Oncol. 2016 Jun;18(6):849-54. doi: 10.1093/neuonc/now007. Epub 2016 Feb 21.

38.

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.

Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, Thabet A, Cahill DP, Perry AM, Joseph CP, Muzikansky A, Chi AS.

Oncologist. 2016 Feb;21(2):214-9. doi: 10.1634/theoncologist.2015-0342. Epub 2016 Feb 1.

39.

Predictors Of Treatment Failure After Radiofrequency Ablation For Intramucosal Adenocarcinoma in Barrett Esophagus: A Multi-institutional Retrospective Cohort Study.

Agoston AT, Strauss AC, Dulai PS, Hagen CE, Muzikansky A, Fudman DI, Abrams JA, Forcione DG, Jajoo K, Saltzman JR, Odze RD, Lauwers GY, Gordon SR, Lightdale CJ, Rothstein RI, Srivastava A.

Am J Surg Pathol. 2016 Apr;40(4):554-62. doi: 10.1097/PAS.0000000000000566.

PMID:
26645729
40.

Retinal Dystrophy and Optic Nerve Pathology in the Mouse Model of Mucolipidosis IV.

Grishchuk Y, Stember KG, Matsunaga A, Olivares AM, Cruz NM, King VE, Humphrey DM, Wang SL, Muzikansky A, Betensky RA, Thoreson WB, Haider N, Slaugenhaupt SA.

Am J Pathol. 2016 Jan;186(1):199-209. doi: 10.1016/j.ajpath.2015.09.017. Epub 2015 Nov 20.

41.

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.

J Thorac Oncol. 2015 Dec;10(12):1670-4. doi: 10.1097/01.JTO.0000473485.38553.f0.

42.

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.

Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Jänne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U, Fleisher M, Yu HA, Wei W, Johnson BE, Barber TA, Walsh JR, Engelman JA, Stott SL, Kapur R, Maheswaran S, Toner M, Haber DA.

Clin Cancer Res. 2016 Mar 1;22(5):1103-10. doi: 10.1158/1078-0432.CCR-15-1031. Epub 2015 Oct 7.

43.

Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.

Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY.

Cancer. 2015 Dec 1;121(23):4165-72. doi: 10.1002/cncr.29636. Epub 2015 Aug 26.

44.

Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.

Gounder MM, Nayak L, Sahebjam S, Muzikansky A, Sanchez AJ, Desideri S, Ye X, Ivy SP, Nabors LB, Prados M, Grossman S, DeAngelis LM, Wen PY.

J Clin Oncol. 2015 Oct 1;33(28):3186-92. doi: 10.1200/JCO.2015.61.1525. Epub 2015 Aug 17.

45.

Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.

Giavina-Bianchi M, Giavina-Bianchi P, Sotto MN, Muzikansky A, Kalil J, Festa-Neto C, Duncan LM.

J Immunol Res. 2015;2015:761378. doi: 10.1155/2015/761378. Epub 2015 Apr 14.

46.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, Parks MK, DiCecca RH, Dias-Santagata D, Iafrate AJ, Shaw AT, Allen AR, Engelman JA, Sequist LV.

Cancer Discov. 2015 Jul;5(7):713-22. doi: 10.1158/2159-8290.CD-15-0399. Epub 2015 May 1.

47.

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.

Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY.

Clin Cancer Res. 2015 Aug 15;21(16):3610-8. doi: 10.1158/1078-0432.CCR-14-3220. Epub 2015 Apr 24.

48.

Clinical significance of microscopic melanoma metastases in the nonhottest sentinel lymph nodes.

Luo S, Lobo AZ, Tanabe KK, Muzikansky A, Durazzo T, Sober A, Tsao H, Cosimi AB, Lawrence DP, Duncan LM.

JAMA Surg. 2015 May;150(5):465-72. doi: 10.1001/jamasurg.2014.3843.

PMID:
25831227
49.

Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy.

Ager EI, Kozin SV, Kirkpatrick ND, Seano G, Kodack DP, Askoxylakis V, Huang Y, Goel S, Snuderl M, Muzikansky A, Finkelstein DM, Dransfield DT, Devy L, Boucher Y, Fukumura D, Jain RK.

J Natl Cancer Inst. 2015 Feb 20;107(4). pii: djv017. doi: 10.1093/jnci/djv017. Print 2015 Apr.

50.

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.

Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY.

Neuro Oncol. 2015 Jun;17(6):862-7. doi: 10.1093/neuonc/nou350. Epub 2015 Jan 7. Erratum in: Neuro Oncol. 2015 Dec;17(12):1650.

Supplemental Content

Loading ...
Support Center